Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
NCT00836043 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6
Last updated 2013-12-03
Summary
This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.
Conditions
Interventions
- DRUG
-
Alemtuzumab (MabCampath)
Intravenous therapy according to product information.
Sponsors & Collaborators
-
Genzyme, a Sanofi Company
lead INDUSTRY
Principal Investigators
-
Medical Monitor · Genzyme, a Sanofi Company
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-10-31
- Primary Completion
- 2009-04-30
- Completion
- 2009-04-30
Countries
- Bosnia and Herzegovina
- Israel
- North Macedonia
More Related Trials
-
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
NCT05367401 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00923182 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
NCT01056510 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Efficacy and Safety of CTL019 in Adult ALL Patients
NCT02167360 ·Status: WITHDRAWN ·Phase: PHASE2
-
Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
NCT00206726 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
NCT03154827 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02556346 ·Status: WITHDRAWN ·Phase: PHASE1
-
Campath Maintenance in Chronic Lymphocytic Leukemia
NCT00587847 ·Status: TERMINATED ·Phase: NA
-
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT05086315 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
NCT03441048 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
NCT01982175 ·Status: SUSPENDED ·Phase: PHASE2
-
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
NCT00738374 ·Status: COMPLETED ·Phase: PHASE2
-
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
NCT02669264 ·Status: TERMINATED ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia
NCT00006097 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02013167 ·Status: TERMINATED ·Phase: PHASE3
-
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00983528 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia
NCT00336206 ·Status: UNKNOWN ·Phase: NA
-
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
NCT06205290 ·Status: WITHDRAWN ·Phase: PHASE3
-
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT01466179 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia
NCT05007860 ·Status: COMPLETED
-
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
NCT01471782 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
NCT00217646 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL
NCT06930105 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Cilengitide in Treating Patients With Acute Myeloid Leukemia
NCT00089388 ·Status: TERMINATED ·Phase: PHASE2
-
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
NCT00303966 ·Status: TERMINATED ·Phase: PHASE2